Strata Skin Sciences, INC

Strata Skin Sciences, Inc. announced its voluntary delisting from The Nasdaq Capital Market due to failure to meet minimum stockholders' equity requirements and an inability to secure sufficient funding without significant dilution.

Strata Skin Sciences, Inc. announced a significant market expansion opportunity with new CPT codes effective January 2027, alongside positive operational cash flow and a favorable injunction in the LaserOptek lawsuit.

STRATA SKIN SCIENCES, INC. stockholders approved the election of five directors, an increase in shares for the incentive plan, and the ratification of its independent auditor at the annual meeting.

STRATA Skin Sciences reported a 21% revenue decline in Q3 2025 to $6.9 million, alongside positive EBITDA and significant progress on CPT code expansion for its XTRAC laser.

Strata Skin Sciences, Inc. filed a prospectus supplement for its at-the-market equity distribution agreement, enabling the potential sale of up to $11.0 million in common stock.

Strata Skin Sciences, Inc. received an extension from Nasdaq until February 16, 2026, to regain compliance with the minimum stockholders' equity requirement.

STRATA Skin Sciences reported a net loss of $1.6 million in Q3 2025 on reduced revenues, but secured its liquidity for the next 12 months by pausing debt covenants and raising capital.

STRATA Skin Sciences reported a significant increase in net losses and a shift to negative working capital for the quarter ended June 30, 2025, alongside declining revenues and an un-remediated material weakness in internal controls.

Strata Skin Sciences' Q1 2025 results show stable revenue with a reduced net loss compared to the same period last year.

Strata Skin Sciences reports a slight decrease in revenue for the third quarter of 2024 compared to the same period last year, alongside a net loss, but shows improved gross profit margins.

Strata Skin Sciences experienced a slight revenue increase in Q2 2024, but faced challenges with profitability and a decrease in XTRAC system placements.

Strata Skin Sciences reported a net loss of $3.368 million for the first quarter of 2024, impacted by lower revenues and increased costs.

Strata Skin Sciences files an amendment to its 2024 annual report to include information required by Part III of Form 10-K, covering details about directors, executive compensation, and related matters.

STRATA Skin Sciences faced net losses in 2024 amid ongoing challenges including the Russia-Ukraine war's impact on gas supplies and evolving healthcare regulations.

Strata Skin Sciences has filed an amendment to its annual report to include information required by Part III of Form 10-K, detailing changes in directors, executive compensation, and other corporate governance matters.

Strata Skin Sciences experienced a net loss of $10.8 million in 2023, while managing supply chain issues and transitioning its international sales model.

Director Samuel Rubinstein sold 14,094 STRATA Skin Sciences shares and bought 5,000 the next day, ending with 8,766 shares at ~$1.32–$1.41 on Nov. 17–18, 2025.

Shmuel Gov, Chief Operating Officer of Strata Skin Sciences, Inc., reports the acquisition of 40,000 stock options on May 13, 2025.

John T. Gillings, Chief Accounting Officer of Strata Skin Sciences, Inc., acquired 30,000 stock options on May 13, 2025.

Dolev Rafaeli, CEO of Strata Skin Sciences, reports acquisition of stock options and adjustments to ownership figures following a reverse stock split.

Christina L Allgeier, a director of Strata Skin Sciences, acquired 20,000 stock options on October 29, 2024.

Uri Geiger, a director and 10% owner of Strata Skin Sciences, indirectly acquired 230,573 shares of common stock at a price of $3.14 per share.

STRATA Skin Sciences, Inc. will hold its 2025 Annual Meeting to elect directors, approve an increase of 520,000 shares for its equity incentive plan, and ratify its independent auditor.

STRATA Skin Sciences announces its 2024 Annual Meeting of Stockholders to be held on October 29, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Accelmed Partners' beneficial ownership in STRATA Skin Sciences adjusted to 27.4% following a registered direct offering that increased outstanding shares.

CVI Investments and Heights Capital Management report 0% ownership in STRATA Skin Sciences, signaling a complete divestment.

CVI Investments, managed by Heights Capital Management, Inc., has disclosed a 6.9% passive beneficial ownership stake in Strata Skin Sciences, Inc.

Lincoln Alternative Strategies LLC has reported a 6.9% beneficial ownership stake in STRATA Skin Sciences, Inc., holding 365,849 shares of common stock.